Assessment of the revision of the 2025 CLSI breakpoints for the interpretation of minocycline susceptibility for <i>Acinetobacter baumannii</i> complex
The Clinical and Laboratory Standards Institute (CLSI) has made a comprehensive revision of minocycline breakpoints for <i>Acinetobacter</i> species in 2025. This update may have a significant impact on antimicrobial susceptibility testing interpretation and treatment strategies for clinical laboratories. However, there is currently a lack of comparative studies about it. Therefore, this study aims to evaluate the impact of the 2025 CLSI breakpoints revision on the interpretation of minocycline for <i>Acinetobacter baumannii</i> complex and to provide experimental evidence for the clinical applicability of new breakpoints.
Authors
- Yi Liu (ORCID: https://orcid.org/0000-0002-1058-0382)
- Xiaochen Yu
- Fupin Hu
- Jinye Du
- Dandan Yin
Institutions
- Nanchang University (CN)
- Harbin Medical University (CN)
- Fudan University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1128/spectrum.02700-25
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00